Guided Biopsy for Mapping Prostate Cancer (HIT)
Evaluate the accuracy of HIT guided biopsies for mapping tumor foci with men undergoing prostatectomy.
|Study Design:||Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
|Official Title:||Hybrid Imaging Technique (HIT) Guided Biopsy to Map Prostatic Adenocarcinoma in Patients Undergoing Prostatectomy|
- Determine the accuracy of hybrid image technology (HIT) guided biopsies for prostate cancer mapping. [ Time Frame: Six years ] [ Designated as safety issue: No ]
|Study Start Date:||May 2010|
|Study Completion Date:||February 2014|
|Primary Completion Date:||February 2014 (Final data collection date for primary outcome measure)|
Experimental: Prostate cancer
A total of 30 patients diagnosed with prostate cancer who have elected to undergo radical prostatectomy are enrolled over a six year period.
The objective of this study is to determine the accuracy of HIT (Hybrid Imaging Technology) guided biopsies for mapping tumor foci with men undergoing prostatectomy. Using a prostate hybrid imaging technology (HIT) which fuses a previously obtained endorectal MR image to transrectal ultrasound (TRUS) image to allow identification and biopsy of tumors by MR imaging in real time. We hypothesis that HIT guided biopsies will accurately localize the foci of prostate cancer.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01007214
|United States, New York|
|Roswell Park Cancer Institute|
|Buffalo, New York, United States, 14141|
|Principal Investigator:||Anurag K Singh, MD||Roswell Park|